Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 31;10(4):e005132.
doi: 10.1136/rmdopen-2024-005132.

Does tocilizumab eliminate inflammation in GCA? A cohort study on repeated temporal artery biopsies

Affiliations

Does tocilizumab eliminate inflammation in GCA? A cohort study on repeated temporal artery biopsies

Caterina Ricordi et al. RMD Open. .

Abstract

Background: Vascular inflammation persists in temporal artery biopsy (TAB) of giant cell arteritis (GCA) patients even after prolonged glucocorticoid (GC) therapy. We aimed to evaluate the histological impact of adding tocilizumab (TCZ) to GCs.

Methods: We enrolled all consecutive GCA patients with an inflammed TAB at diagnosis who were treated with TCZ and GCs for ≥6 months and followed from December 2017 to December 2023. Within 2 weeks, all patients underwent a second TAB, positron emission 18-fluorodeoxyglucose tomography/CT (PET/CT) and vessel colour Doppler ultrasonography (CDUS). Results were compared with pretreatment findings.

Results: 13 patients repeated TAB after a median TCZ treatment of 2.4 years (Q1-Q3: 1.2-3.9 years). The first TAB showed transmural inflammation (TMI) in 11/13 patients (84.6%), inflammation limited to adventitia (ILA) in one patient (7.7%) and small vessel vasculitis (SVV) in another (7.7%). On repeated TABs, five patients (38.5%) still showed some degree of inflammation. Among the 11 patients with initial TMI, 2 had ILA, 1 had TMI, 1had SVV and 1 had vasa vasorum vasculitis at the second TAB. Nine patients had active vasculitis at baseline PET/CT, and three (33.3%) still showed activity at the last PET/CT, with a relevant reduction in mean PET vascular activity score (-6.5; 95% CI 1.54 to 11.45; p=0.017). The repeated quantitative CDUS revealed altered parameters suggestive of vasculitis in temporal arteries in about one-third of the patients.

Conclusion: Our study, using pathological and imaging assessments, revealed that after TCZ and GCs, over one-third of patients still presented with vascular inflammation.

Keywords: Biological Therapy; Giant Cell Arteritis; Glucocorticoids; Ultrasonography.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1. Histological modifications of temporal artery biopsies during tocilizumab and glucocorticoid treatment: relationship with disease activity. Data are reported as % (n) . GCA, giant cell arteritis; ILA, inflammation limited to adventitia; NEG, negative; SVV, small vessel vasculitis; TMI, transmural inflammation; VVV, vasa vasorum vasculitis.
Figure 2
Figure 2. Histological patterns at the first and at the second temporal artery biopsies of the four patients with giant cell arteritis and persistent inflammation of temporal arteries. (A, C, E, G) Evidence of transmural inflammation at the first biopsy in all four patients; (B, D, F, H) Respective histological pattern at the second biopsy: transmural inflammation (B), inflammation limited to adventitia (D), small vessel vasculitis (F) and vasa vasorum vasculitis (H) (H&E, ×200–400).

References

    1. Salvarani C, Cantini F, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. Lancet. 2008;372:234–45. doi: 10.1016/S0140-6736(08)61077-6. - DOI - PubMed
    1. Muratore F, Kermani TA, Crowson CS, et al. Large-vessel giant cell arteritis: a cohort study. Rheumatology (Oxford) 2015;54:463–70. doi: 10.1093/rheumatology/keu329. - DOI - PMC - PubMed
    1. Hellmich B, Agueda A, Monti S, et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2020;79:19–30. doi: 10.1136/annrheumdis-2019-215672. - DOI - PubMed
    1. Maz M, Chung SA, Abril A, et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis. Arthritis Rheumatol . 2021;73:1349–65. doi: 10.1002/art.41774. - DOI - PubMed
    1. Ponte C, Grayson PC, Robson JC, et al. 2022 American College of Rheumatology/EULAR classification criteria for giant cell arteritis. Ann Rheum Dis. 2022;81:1647–53. doi: 10.1136/ard-2022-223480. - DOI - PubMed

MeSH terms